Phase 1 Healthcare
Our Impact
At Truusome AI, impact is measurable. Our platforms consistently demonstrate double-digit improvements in key performance indicators, whether that means improved health outcomes, reduced inefficiencies, or stronger compliance. Across pilots and deployments, we have delivered results that translate into both individual well-being and systemic cost savings for enterprises and governments.
Our Focus
We are committed to simplifying complexity. By targeting core drivers of systemic risk and inefficiency, we reduce the likelihood of widespread failures.
Starting with the Nutraceutical & FMCG Sector, we aim to provide platforms that allow client’s SKUs to decrease the chances of people suffering from 5/10 widespread diseases in the Global South.
Our Research Facility
Innovation is grounded in science. Our 7,500+ sq ft research and development facility brought together leading practitioners in computational biology, microbiology, and data science. Leveraging advanced methods in biological modeling, encapsulation technologies, and algorithmic simulation, we validated our approaches before scaling them into enterprise-ready platforms.
Our Impact Factor
Clinical trials and studies have proved that adding just 34 grams of our algorithm's recommendation could provide our client’s SKUs with an average of 30% increase in target nutrition improvement.
The efficiency improvement increases to 40% when clients use our algorithms to target a single nutrient!
Our Validation
We believe in evidence, not assumptions. Our solutions were subjected to clinical trials, longitudinal studies, and controlled pilots to ensure their reliability.
13-week Clinical trials demonstrated significant improvements in nutritional indices and measurable adherence rates when our systems were integrated into everyday consumption.
Welcome!
As of August 19, 2023, Truusome AI’s proprietary algorithms and platform technology were acquired by Orion Pharmaceuticals & Nutraceuticals (India). Under the terms of the agreement, Orion retains exclusive commercial rights for a period of five years, after which the intellectual property will transition to an open-source framework (subject to mutual agreement). This site provides a static archive of our earlier work, with certain details withheld due to confidentiality obligations under the acquisition terms. For updates regarding the future open-source release, or to explore potential collaborations, please contact us directly.
Hello! This is no longer an interactive chatbot. Use the button below to contact us on WhatsApp if you're interested in accessing our open-source algorithm for drug development after the exclusivity period.
